FDLI Pharmaceutical Update
Agenda topics for FDLI's May 30-31 meeting include OTC advertising, approvals and enforcement and direct-to-consumer advertising of Rx drugs. Speakers include FDA Drug Labeling Compliance Div. Director Rudolph Apodaca, and FDA Office of Drug Standards Director Peter Rheinstein. Conference will be at D.C. Shoreham Hotel.
You may also be interested in...
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.